Dry age related macular degeneration

This study tests the long-term safety of vonaprument, an experimental drug given as an injection into the eye, for people with geographic atrophy, a severe form of dry age-related macular degeneration that causes blind spots. Researchers will monitor participants who completed an…

This early-stage trial tests a gene therapy called AGX-08 for geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. The study will involve 24 people aged 50 and older, each receiving a single injection into one eye. The main goal is to …

This trial tests a gene therapy called PST-611 in people aged 65 and older with geographic atrophy, an advanced form of age-related macular degeneration that causes blind spots. PST-611 is a DNA plasmid injected into the eye muscle that instructs cells to produce human transferri…

This trial investigates whether a personal-use electric stimulator, worn at home for 30 minutes daily, can improve vision in people with early to intermediate dry age-related macular degeneration (AMD). Participants are randomly assigned to receive either real or sham stimulation…

This early study tests whether stimulating a nerve cluster behind the cheekbone (the pterygopalatine ganglion) is safe and doable for people with geographic atrophy, a severe form of age-related macular degeneration that causes blind spots. Sixty-two adults will receive either re…

This study tests a new, non-invasive treatment for dry age-related macular degeneration (AMD), a common cause of vision loss in older adults. About 94 people aged 50 and older with dry AMD will use a red-light device at home twice daily for three months. Researchers will check if…

This study tests whether mirabegron, a drug used for overactive bladder, can help people with dry age-related macular degeneration (AMD). Researchers will give 312 patients aged 50-80 either mirabegron or a standard bladder drug for 12 months and check for changes in the retina. …

This study tests an experimental pill (EG-301) taken daily for at least 6 months in 90 people with dry age-related macular degeneration (AMD) and geographic atrophy. Participants are randomly assigned to receive either standard AREDS2 supplements alone or AREDS2 plus EG-301. The …

This study will test a new, non-invasive eye scanner called wide field OCTA in 200 people with various eye diseases, including age-related macular degeneration, diabetic retinopathy, and dry eye. The goal is to see if this device can provide better images of blood vessels in the …

This study aims to see if virtual reality tests can better measure how age-related macular degeneration affects daily life compared to standard eye exams. Researchers will enroll 60 participants, including healthy adults and those with the eye condition. The goal is to develop a …